The purpose of the study is to compare how long the disease stays under control when the venetoclax tablets are continued for a longer time versus when they are stopped after the initial six cycles combined with rituximab. After the first six cycles of both medicines, participants are randomly assigned to either keep taking venetoclax for many more cycles or to stop the drug and be observed.

During the trial, participants visit the clinic regularly for safety checks, blood tests, and to monitor the cancer’s activity. Those who continue the medication follow the longer schedule, while those who stop stop after the initial period. All participants are followed for several years to see whether the cancer progresses, to record any side effects, and to assess overall health and quality of life.

The purpose of this research is to determine how well NX-5948 works in treating adults with CLL or SLL that has come back or not responded to previous treatments. During the study, participants will receive NX-5948 capsules daily. The maximum daily dose that may be given is 600 milligrams, and treatment may continue for up to 28 days per treatment cycle.

Throughout the study, doctors will monitor participants’ health through regular check-ups and various medical tests. They will look at how the cancer responds to the treatment and keep track of any side effects that may occur. The study will collect information about how long the treatment effects last and how it affects participants’ overall health.

The medications will be given in different ways – some as tablets taken by mouth and others through an intravenous infusion (given directly into a vein) or subcutaneous injection (given under the skin). The study will be conducted in two parts. The first part will determine the right dose of the drug combinations, while the second part will further study how well these doses work and what side effects they may cause.

Throughout the study, doctors will monitor patients’ health, check how well the treatment is working, and track any side effects. They will look at how many patients respond to treatment and how long the response lasts. For some patients, they will also measure the amount of cancer cells remaining in the blood or bone marrow after treatment.

The purpose of the study is to evaluate how effective the combination of Ibrutinib and Venetoclax is in reducing the number of cancer cells to very low levels, a state known as minimal residual disease (MRD) negativity. This means that the cancer cells are reduced to such a low number that they are almost undetectable. The study will follow a specific plan where patients will receive these medications and be monitored to see how well the treatment works over time.

Participants in the study will take the medications as directed and will have regular check-ups to monitor their health and the effects of the treatment. The study aims to provide more information on how well this combination of medications can help patients with relapsed or refractory CLL. The trial is open-label, meaning both the researchers and participants know which treatment is being given, and it is not controlled by a placebo group.

The purpose of the study is to evaluate how well Acalabrutinib works on its own compared to the other treatment options. Participants in the study will be randomly assigned to receive either Acalabrutinib or one of the standard treatment combinations. The study will monitor the progress of the disease and any side effects experienced by the participants over a period of time. The medication Acalabrutinib is taken orally in the form of hard capsules.

Throughout the study, participants will undergo regular assessments to track their health and the status of their Chronic Lymphocytic Leukemia. The study aims to provide valuable information on the effectiveness of Acalabrutinib compared to existing treatment options, potentially offering new insights into managing this condition. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

The purpose of this study is to evaluate the long-term safety of these therapies. Patients who have received these treatments will be monitored over time to check for any late-onset side effects or serious health events. This includes looking for any new or returning cancers, serious infections, or other significant health issues. The study will also track the presence of certain cells in the blood, such as B and T lymphocytes, and other health indicators like height and weight in children. The presence of any remaining modified cells from the therapy will also be checked.

Participants in this study will have regular follow-up visits where their health will be assessed. This includes checking for any signs of the cancer returning or progressing and monitoring overall survival rates. The study aims to ensure that the treatments are safe in the long term and to gather important information that can help improve future therapies. The study is expected to continue until the end of 2040, providing valuable insights into the long-term effects of these innovative treatments.

The purpose of the study is to determine the safety and effectiveness of this new treatment in both adults and children who have these types of blood cancers and have not responded to other treatments. Participants will receive the PTG-CARCIK-CD19 treatment and will be monitored to see how well the treatment works and how long the modified cells stay active in the body. Some participants may receive a placebo, which is a substance with no active treatment, to compare the effects.

The study will take place over several years, with regular check-ups to monitor the participants’ health and response to the treatment. The goal is to find out if this new approach can help improve the overall response rate, which means how well the cancer responds to the treatment, in patients with these challenging conditions. Participants will be closely observed for any side effects or changes in their condition throughout the study period.